Self-reported pediatricians' management of the well-appearing young child with fever without a source: first survey in an European country in the anti-pneumococcal vaccine era by Chiappini, Elena et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Public Health
Open Access Research article
Self-reported pediatricians' management of the well-appearing 
young child with fever without a source: first survey in an European 
country in the anti-pneumococcal vaccine era
Elena Chiappini1, Luisa Galli1, Francesca Bonsignori1, Elisabetta Venturini1, 
Nicola Principi2 and Maurizio de Martino*1
Address: 1Department of Pediatrics, University of Florence, Florence, Italy and 2Department of Maternal and Pediatric Sciences, University of 
Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
Email: Elena Chiappini - echiappini@unifi.it; Luisa Galli - luisa.galli@unifi.it; Francesca Bonsignori - francescabonsignori@yahoo.it; 
Elisabetta Venturini - elisabetta-venturini@virgilio.it; Nicola Principi - nicola.principi@unimi.it; Maurizio de 
Martino* - maurizio.demartino@unifi.it
* Corresponding author    
Abstract
Background: Recent studies suggest a substantially reduced risk of invasive bacterial infection in
children vaccinated with heptavalent pneumococcal conjugate vaccine (PCV). To investigate
whether the introduction of PCV might affect clinical decision making, we conducted a cross-
sectional survey aimed at Italian Pediatric physicians.
Results:  The study included 348 (46.5%) primary care pediatricians; 251 (36.4%) hospital
pediatricians, and 139 (20.1%) pediatric residents. In an hypothetical scenario, a well-appearing 12-
month-old child with fever without source would be sent home with no therapy by 60.7% (419/
690) of physicians if the child was not vaccinated with PCV. The proportion increased to 74.2%
(512/690) if the child had received PCV (P < 0.0001). Also, physicians would obtain blood tests less
frequently in the vaccinated than in unvaccinated children (139/690 [20.1%] vs. 205/690 [29.7%]; P
< 0.0001), and started empiric antibiotic therapy less frequently (3.0% vs. 7.5%; P < 0.0001). In the
hypothetical event that white blood cell count was 17,500/μL, a significantly lower proportion of
physicians would ask for erythrocyte sedimentation rate (P < 0.017), C reactive protein (P <
0.0001), blood culture (P = 0.022), and urine analysis or dipstick (P = 0.028), if the child had
received PCV. Only one third of participants routinely recommended PCV.
Conclusion: Our data suggest that implementation of educational programs regarding the proper
management of the febrile child is needed.
Background
The management of children with a fever without a source
remains controversial [1], and it is becoming even more
so after the introduction of the hepta-valent pneumococ-
cal conjugate vaccine (PCV) [1]. It has been calculated that
the widespread use of PCV is associated with a decreased
risk of bacterial infection from about 2–5% to less than
1% in well-appearing young children with a fever without
a source [1]. Given this minimal risk, some authors hope
that the management of these children will become a
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non-entity in the near future, and screening blood tests
(e.g. complete blood cell count with differential, blood
culture), and empiric antibiotic treatment will become
unnecessary [2].
However, available data are insufficient to support modi-
fications of current clinical practice guidelines. Also of
concern, increasing rates of infections due to antimicro-
bial resistant pneumococcal serotypes not-included into
the heptavalent PCV have been reported [3-6]
To the best of our knowledge two surveys previously
investigated physicians' self-reported attitudes toward the
management of young children presenting with a fever
without a source, since the introduction of PCV [7,8].
Both the studies were conducted in the United States and
found that pediatricians would order fewer complete
blood cell counts, blood cultures, and urine tests, and
would prescribe less antibiotics in the event that the child
is vaccinated with PCV [7,8]. Thus the introduction of
PCV seems to affect pediatricians' decision making in the
United States. No similar study has been conducted in an
European country. Therefore, we carried out a cross-sec-
tional survey on a sample of Italian pediatricians regard-
ing the management of a hypothetical well-appearing,
young child presenting with a fever without a source, with
relation to his/her anti-pneumococcal vaccination status.
Methods
Study population
The sample included representatives from the two differ-
ent categories of pediatricians operating in Italy (primary
care pediatricians, and hospital pediatricians), as well as a
group of post-graduate physicians, specializing in pediat-
rics. All of the pediatricians and pediatric residents regis-
tered at the Annual Congress of the Italian Society of
Pediatrics held in Pisa, Italy, September 26–29, 2007,
were considered eligible for enrollment. This Congress is
usually attended by 20–25% of the Italian pediatricians
and a similar proportion of pediatric residents [9]. Over-
all, 1500 questionnaires were distributed.
Questionnaire and its administration
A self-administered, anonymous questionnaire was dis-
tributed to all the physicians at the Congress registration
desk. The questionnaire included an explanatory cover let-
ter and was prepared by the authors on the basis of a sim-
ilar clinical scenario presented to United States
pediatricians in a previous study by Wittler and colleagues
[10]. The questionnaire was previously pilot-tested on a
convenient sample of primary care pediatricians, hospital
pediatricians and pediatric residents in order to ensure
clarity and ease of administration. The English version of
the clinical scenario is shown in Additional File 1. The sur-
vey was administered in Italian and translated into Eng-
lish for publication. Responses were anonymous, but
demographic (age, gender, graduation year) and profes-
sional (primary care pediatrician, hospital pediatrician, or
pediatric resident) information was requested.
Participants were asked whether they would send the chil-
dren home and follow-up ("wait-and see"), would obtain
blood tests, or would treat them empirically with antibi-
otic therapy. Subsequently, pediatricians were asked to
mark on a checklist whether they would perform, erythro-
cyte sedimentation rate, C reactive protein, blood culture,
urine analysis or dipstick, urine culture, stool culture,
group A β-haemolitic streptococcus rapid test, chest X-ray,
abdomen ultrasound scan, or lumbar puncture or
whether they would observe and re-evaluate the child
later without performing laboratory studies. A blank space
was provided in which to write in additional studies
thought to be appropriate. A hypothetical blood test exam
showing white blood cell count of 17.500/μL (with 45%
segmented neutrophils, 15% band forms and 40% lym-
phocytes) was provided. This scenario was similar to that
one previously developed by Wittler and colleagues [10].
Participants were also asked whether, in such scenario,
they would send children home and subsequently follow-
up, treat them empirically with an antimicrobial or would
admit them to hospital. They were also asked to specify
which antibiotic they would use for empiric therapy. An
additional question was exclusively directed to primary
care pediatricians, addressing whether they usually use
rapid tests in their offices. A final question explored the
participants' general attitudes toward PCV recommenda-
tion. The study was in compliance with the Helsinki Dec-
laration and was approved by the Ethical committee of the
Meyer Children Hospital, Florence, Italy. All the physi-
cians gave their informed consent to fill out an anony-
mous survey.
Statistical methods
Results were stratified by the participants' professional
category. Differences in responses regarding the PCV vac-
cination status evaluated by contingency table analysis
with the χ2 or the Fisher's exact test, as appropriate. SPSS®
software package ((SPSS 11.5; Chicago, IL) was used, and
P < 0.05 was considered as statistically significant.
Results
Participants' characteristics
Overall, 690 pediatricians or pediatric residents (46.0% of
physicians registered to the Congress) returned the ques-
tionnaire. Median age was 48.4 years (interquartile range
[IQR]: 35.7–54.0), and 415 (60.06%) were females. Three
hundred (46.48%) were primary care pediatricians; 251
(36.38%) were hospital pediatricians and 139 (20.14%)
were pediatric residents.BMC Public Health 2009, 9:300 http://www.biomedcentral.com/1471-2458/9/300
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Initial approach to the well-appearing young child with 
fever without source, with relation to his/her PCV 
vaccination status
The proportion of participants who report to "wait-and
see" was 60.7% (419/690), if the child was not vaccinated
with PCV and increased to 74.2% (n = 512/690) if the
child had received PCV (P < 0.0001). Also, physicians
would obtain blood tests less frequently in the vaccinated
than in the not-vaccinated child (139/690 [20.1%] vs.
205/690 [29.7%]). Empiric antibiotic therapy would be
started by 3.0% (21/690) of pediatricians/pediatric resi-
dents if the child had received PCV vs. 7.5% of participants
(52/690) if the child was unvaccinated (P < 0.0001)
(Table 1). No significant difference was evidenced among
physician categories (P = 0.105 considering not-vacci-
nated child; P = 0.396 considering the vaccinated child, by
Pearson χ2 test among categories).
Approach to the well-appearing young child with fever 
without source and white blood cell count = 17,5000/μL, 
with relation to his/her PCV vaccination status
Participants were asked how they would have managed
the child if he/she had shown white blood cell count of
17,500/μL. The proportion of physicians who reported to
send the child home with no antibiotic therapy raised
from 33.2% (229/690) for the not-vaccinated to 46.5%
(321/690) for the vaccinated child (P < 0.0001). A signif-
icantly lower proportion of physicians reported to ask for
erythrocyte sedimentation rate (P < 0.017), C reactive pro-
tein (P < 0.0001), blood culture (P = 0.022), urine analy-
sis/or dipstick (P = 0.028), in the child vaccinated with
PCV (Table 2). Investigations would be obtained after 2.2
days of fever (median 2.2; IQR:2.0–3.5 days) with no sig-
nificant difference regarding the PCV vaccination status.
No significant difference was observed among physicians'
categories.
Preferred antibiotic treatment for empiric therapy
Oral therapy with amoxicillin or amoxicillin/clavulanic
acid was the preferred option by 609/690 (88.3%) partic-
ipants. Ceftriaxone was chosen by 16/690 (2.3%) physi-
cians (Table 3). No significant difference was observed
among physicians' categories (P = 0.864).
Use of quick tests by primary care pediatricians in the 
office setting
In general, among the 300 primary care pediatricians who
returned the questionnaire, quick test for C reactive pro-
tein was reported to be routinely performed by 100/300
(33.33%), urine dipstick test by 293/300 (97.33%), and
Group A β haemolitic streptococcus rapid test by 206/300
(68.67%).
Attitude toward PCV recommendation
Four-hundred-sixty-one (66.81%) participants reported
that they to recommend PCV vaccination to all children,
while 208 (30.14%) recommend it only in the presence of
siblings or day care attendance. Seventeen (2.46%) physi-
cians would never recommend PCV. Finally, 2 (0.29%)
pediatricians recommend PCV only in children with a
chronic disease, and 2 (0.29%) did not answer. No signif-
Table 1: Change in physicians' self-reported, initial approach to the well-appearing young child, with relation to PCV vaccination 
status
Not vaccinated child Vaccinated child
Primary care 
pediatricians
Hospital 
pediatricians
Pediatric 
residents
Total Primary care 
pediatricians
Hospital 
pediatricians
Pediatric 
residents
Total
Blood 
examination
n (%)
76 (25.3) 82 (32.7) 47 (33.8) 205 (29.7) 55 (18.3) 52 (20.7) 32 (23.0) 139 (20.1)
Empiric 
antibiotic 
treatment
n (%)
19 (6.3) 19 (7.6) 14 (10.1) 52 (7.5) 7 (2.3) 7 (2.8) 7 (5.0) 21 (3.0)
Wait-and see
n (%)
197 (65.7) 147 (58.6) 75 (54.0) 419 (60.7) 228 (76.0) 188 (74.9) 96 (69.1) 512 (74.2)
Not answer
n (%)
8 (2.7) 3 (1.2) 3 (2.2) 14 (2.0) 10 (3.3) 4 (1.6) 4 (2.9) 18 (2.6)
P * 0.013 <0.0001 0.021 <0.0001
Note. * vaccinated vs. non vaccinated child, by Pearson χ2 testBMC Public Health 2009, 9:300 http://www.biomedcentral.com/1471-2458/9/300
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Table 2: Change in physicians' self-reported approach to the well-appearing young child with white blood cell count of 17,500/μL, with 
relation to PCV vaccination status
Not Vaccinated child
(n = 690)
Vaccinated child
(n = 690)
Wait-and see (n;%) 229 (33.2%) 321 (46.5%)
Empiric antibiotic therapy (n;%) 381 (55.2%) 337 (48.8%)
Hospital admission (n;%) 80 (11.6%) 32 (4.7%)
P (vaccinated vs. not-vaccinated child) <0.0001
Investigations (ordered at any time during febrile illness) Not Vaccinated child
(n = 690)
Vaccinated child
(n = 690)
P
▪ Blood culture 107 (15.5%) 77 (11.2%) 0.022
▪ C reactive protein 468 (67.8%) 394 (57.1%) <0.0001
▪ Erythrocyte sedimentation rate 163 (23.6%) 126 (18.2%) 0.017
▪ Urine analysis or dipstick 428 (62.0%) 359 (52.0%) 0.028
▪ Urine culture 324 (47.0%) 311 (45.0%) 0.501
▪ Stool culture 12 (1.7%) 14 (2.0%) 0.843
▪ Group A β haemolitic streptococcus rapid test 165 (23.9%) 139 (20.1) 0.104
▪ Chest X ray 56 (8.1%) 41 (5.9%) 0.140
▪ Abdomen ultrasound scan 3 (0.5%) 3 (0.5%) 0.682
▪ Lumbar puncture 7 (1.0%) 6 (0.9%) 1.000
Table 3: Physicians' self-reported preferred antibiotic for therapy empiric treatment.
Primary care pediatricians
n (%)
Hospital pediatricians
n (%)
Pediatric residents
n (%)
Total
N (%)
Ceftriaxone i.m./i.v. 8 (2.7) 7 (2.8) 1 (0.7) 16 (2.3)
Amoxicillin ± clavulanic acid 267 (89.0) 218 (86.9) 124 (89.2) 609 (88.3)
Macrolide 5 (1.7) 5 (2.0) 2 (1.4) 12 (1.7)
Per os cephalosporin 8 (2.7) 10 (4.0) 7 (5.0) 25 (3.6)
Other 1 (0.3) 1 (0.4) 0 2 (0.3)
No answer 11 (3.7) 10 (4.0) 5 (3.6) 26 (3.8)
Note: i.m.: intramuscular; i.v.: intravenousBMC Public Health 2009, 9:300 http://www.biomedcentral.com/1471-2458/9/300
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icant difference was observed among physician categories
(P = 0.475).
An additional analysis was performed, considering
whether response pattern differs among participants who
recommend PCV for all children and those who do not.
The wait-and see option has been chosen by 169/229
(73.8%) pediatricians who do not recommend PVC rou-
tinely vs. 327/461 (70.9%) pediatricians who recommend
PCV routinely (p = 0.485) considering the not-vaccinated
child, and by 147/221 (66.5%) pediatricians who do not
recommend PVC routinely vs. 259/461 (56.2%) pediatri-
cians who recommend PCV routinely considering the vac-
cinated child (p = 0.013).
Discussion
Results of our survey indicate that pediatricians' self-
reported management of the well-appearing young child
with a fever without a source considerably change
whether (s)he had received PCV or not. The majority
(about 60%) of pediatricians/pediatric residents report to
"wait-and see" if the child was not vaccinated with PCV,
and this proportion significantly increased if the child had
received PCV, reaching 76.0%. Parallel to this finding,
physicians would choose to obtain blood tests and begin
empiric antibiotic therapy less frequently in the vacci-
nated than in the not-vaccinated child. Empiric antibiotic
therapy would be started by about 3.0% of participants if
the child had received PCV. The preferred antibiotic treat-
ment for empiric therapy was largely amoxicillin or amox-
icillin/clavulanic acid. In the event that the child showed
white blood cell count of 17,500/μL (making the risk of
bacterial infection higher), one third of participants still
would "wait-and see" and send the unvaccinated child
home with no therapy. This rate reaches about 45% if the
child was vaccinated with PCV, with no significant differ-
ence among results obtained by primary care or hospital
pediatricians, or pediatric residents. A significantly lower
proportion of participants would obtain erythrocyte sedi-
mentation rate, C reactive protein, blood culture, and
urine analysis/or dipstick if the child was vaccinated with
PCV. Only two thirds of the our participants report to rec-
ommend routinely PCV. Additionally, we documented
that self-reported use of quick tests (including C reactive
protein quick test, group A β-haemolitic streptococcus
rapid test, and urine dipstick) is widespread among Italian
primary care pediatricians.
In general, our survey results show that management of
the well-appearing young child with fever without source
is heterogeneous among Italian pediatricians/pediatric
residents. Similar data have been previously reported by
Wittler and colleagues in 1998 [10], after the proposal of
the U.S. guideline for the management of the febrile child
[11]. Later, this guideline has been revisited [2]. Subse-
quently, other algorithms about the management of the
febrile child have been published, including some regard-
ing the "wait-and see" approach [12-15]. This approach
was the preferred option by our participants, who likely
considered the low risk of bacterial infection in this hypo-
thetical child. Nevertheless, the fact that one third of par-
ticipants still chooses this approach when white blood
cell count is 17,500/μL raises concern.
Results similar to ours have been previously reported
among United States pediatricians [7,8]. It is worth noting
that an unintended effect of PVC widespread on the man-
agement of the young children with a fever without a
source may include reduced efforts to diagnose urinary
tract infection, whose pathogenesis and incidence are not
influenced by the child's anti-pneumococcal vaccination
status. Possibly, physicians perceive that the PCV vacci-
nated child is, in general, at minimal risk for all bacterial
infections. Indeed, several types of bacterial infections
should be ruled out, besides Streptococcus pneumoniae
infection, including those due to Neisseria meningitidis,
Escherichia coli, and Staphylococcus aureus [14].
The finding that only two-thirds of our participants report
to recommend routinely PCV suggests that informative
campaign is urgently needed in Italy. This is in strong con-
trast with results from the United States, where one year
after PCV was recommended, nearly all pediatricians had
incorporated this vaccine [15,16].
The preferred antibiotic treatment for empiric therapy was
oral amoxicillin. The low use of macrolides is justified in
Italy, since bacterial resistance to this class of drugs is
wide-spread, as well as in other European countries [17].
The choice of an oral antibiotic with respect to ceftriaxone
is in contrast with current guidelines, recommending
ceftriaxone or another third generation cephalosporin
[14]. Pediatricians might have considered the results of
studies showing equal efficacy of oral and parenteral anti-
biotics in preventing severe bacterial infections in well-
appearing children with Streptococcus pneumoniae occult
bacteraemia [18]. Possibly, they considered the reduced
discomfort from an oral course of antibiotics. However, it
must be remembered that, according to the current guide-
lines, in a child older than three months, presenting with
a fever and suspected serious bacterial infection, antibiot-
ics should cover Neisseria meningitidis, Streptococcus pneu-
moniae, Escherichia coli, Staphylococcus aureus and
Haemophilus influenzae type b. Thus, ceftriaxone or cefo-
taxime should be considered as the first line therapy [14].
Our investigation has potential limitations. First, our
results may not generalize to all pediatricians nationwide.
Participans included in the study constituted approxi-
mately 10% of all the about 7500 Italian pediatriciansBMC Public Health 2009, 9:300 http://www.biomedcentral.com/1471-2458/9/300
Page 6 of 7
(page number not for citation purposes)
working in Italy in 2007 (Italian Pediatric Society secretar-
iat: personal communication), and were all attending the
Annual Congress of the Italian Pediatric Society. There-
fore, our study population may be not representative of all
Italian pediatricians/pediatric residents. Second, it is well
known that self-reported behavior can be misleading
since some participants might not complete the survey as
carefully as they would provide medical care [19]. The fact
that other two similar surveys conducted in the United
States [7,8] and one observational study on children
attending an emergency department in Spain [20] docu-
mented results similar to ours further corroborate our
findings. Finally, the attitude toward urine testing has
been reported to vary among pediatricians, and a poten-
tial limitation of our study is that results may have dif-
fered if the child's age was younger or if the gender was
specified [21].
Encouraging results of large epidemiological studies indi-
cate substantial reduced risk of invasive pneumococcal
infection in children vaccinated with PCV [22]. The effects
of decreased rates of pneumococcal disease on routine
clinical practice are potentially significant [23]. However,
pneumococcal serotype replacement has been docu-
mented [24], and, to date, evidence is lacking to modify
algorithms for the management of the febrile child, con-
sidering his/her PCV vaccination status.
Conclusion
Italian pediatricians may obtain less blood and urine tests
and prescribe less empiric antibiotic treatments in well-
appearing young febrile children if they have received
PCV. However, until more data are available regarding the
actual risk of bacterial infection in children vaccinated
with PVC in developed countries, this approach should
not be sanctioned.
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